Menu Menu Menu
Nice Insight Research
Content Menu
Menu Menu Menu
To Top

Content Filter


2645 Articles available
Acquisition

Therapix Biosciences Provides Update Regarding FSD Acquisition

PR-M12-18-NI-052
Presentation

Abbott to Present at J.P. Morgan Healthcare Conference

PR-M12-18-NI-051
FDA Statement

Statement from FDA Commissioner Scott Gottlieb, M.D., on new actions advancing the agency's biosimilars policy framework

PR-M12-18-NI-049
Appointment

BiomX Appoints Sailaja Puttagunta as Chief Medical Officer

PR-M12-18-NI-048
Companion Diagnostics

Roche to develop companion diagnostic test to help identify patients eligible for anti-PD-1 therapy based on biomarker expression, not location, of solid tumors

PR-M12-18-NI-050
Innovation

Brii Biosciences Builds Innovative Pipeline, Forges Public-Private Partnerships to Bring Novel Medicines to Chinese Patients

PR-M12-18-NI-042
FDA

XOSPATA® (gilteritinib) Available at Biologics by McKesson

PR-M12-18-NI-045
Pricing

Tenax Therapeutics Announces Pricing of $10 Million Underwritten Offering

Expansion

NYCEDC Grants $1M To Quentis Therapeutics For Expansion of LifeSci Space in West Harlem

PR-M12-18-NI-043
Appointment

Kaleido Biosciences Announces Appointment of Katharine Knobil, M.D., as Chief Medical Officer and Head of Research & Development

PR-M12-18-NI-041
FDA Approval

FDA Approves Roche's Tecentriq in Combination with Avastin and Chemotherapy for the Initial Treatment of People with a Specific Type of Metastatic Lung Cancer

PR-M12-18-NI-041
Financing

Impel NeuroPharma Closes $67.5 Million Series D Financing

PR-M12-18-NI-040
Immuno-Oncology

Immuno-oncology Development Trends and Opportunities

PR-M12-18-NI-038
Alzheimer's Disease

First Drug Candidate From Eisai-UCL Research Collaboration To Enter Alzheimer's Disease Clinical Trials

PR-M12-18-NI-037
Financial Results

Amgen Announces 10 Percent Increase In 2019 First Quarter Dividend

PR-M12-18-NI-036
Approval

Genentech Receives Additional Approval for Tecentriq

PAO-M12-18-NI-011
Appointment

Roche Exec Moves to Gilead

PAO-M12-18-NI-010
FDA

FDA Issues Draft Guidance for Companion Diagnostics

PAO-M12-18-NI-009
Spin-off Business

Mallinckrodt Spins off its Generics Business

PAO-M12-18-NI-005-11
Growth

WuXi AppTec Plans for Growth

PAO-M12-18-NI-005-10
Expansion

Investor Group Purchases 110-Acre Pharmaceutical Campus in Huntsville, Alabama

PR-M12-18-NI-047
M&A

Histo-Scientific Research Laboratories and Vet Path Services Merge

PR-M12-18-NI-046
Gene and Cell Therapy

PPD Expands GMP Lab Testing Capabilities for Biologics

PR-M12-18-NI-035
FDA Statement

Statement from FDA Commissioner Scott Gottlieb, M.D., on the FDA's new effort for developing and class labeling of in vitro companion diagnostics for classes of oncology therapeutic products

PR-M12-18-NI-034
Stem Cells

USRM announces U.S. Stem Cell Clinic Expansion of Products and Services

PR-M12-18-NI-033
Market Prediction

Worldwide Opportunity Outlook on the Anti-obesity Drugs Market to 2022 - Key Players are Eisai, Novo Nordisk and Vivus - ResearchAndMarkets.com

PR-M12-18-NI-032
FDA Statement

Statement from FDA Commissioner Scott Gottlieb, M.D., on FDA's new strategic framework to advance use of real-world evidence to support development of drugs and biologics

PR-M12-18-NI-031
FDA Acceptance

FDA Accepts Filing of New Estrogen-free Oral Contraceptive Developed by Exeltis

PR-M12-18-NI-030
FDA Approval

Olympus Spiration® Valve System Is FDA Approved for the Endobronchial Treatment of Emphysema

PR-M12-18-NI-029
Clinical Trial

Prometic to Initiate PBI-4050 Pivotal Phase 3 Clinical Trial in Alström Syndrome

PR-M12-18-NI-028
Appointment

Sartorius Supervisory Board Appoints Two New Executive Board Members

PR-M12-18-NI-027
License Agreement

Ablexis Announces Licensing Agreement with Allogene Therapeutics

PR-M12-18-NI-026
Leukemia

Astellas Presents Updated Results from Phase 1 Study of Gilteritinib Plus Chemotherapy in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)

PR-M12-18-NI-025
Obesity

The Anti-Obesity Drugs Market Will Register a CAGR of Almost 8% by 2023

PR-M12-18-NI-024
Chronic Migraine

Migraine Drugs Market Size Worth $7.8 Billion by 2025 | CAGR: 18.0%: Grand View Research, Inc.

PR-M12-18-NI-023
Microbiome

ISOThrive Study Reveals Novel Bacterial microFood May Relieve Acid Reflux by Restoring the Distal Esophageal Microbiome

PR-M12-18-NI-021
Gastroenterology

Mylan Expands Gastroenterology Portfolio with Launch of Generic for Prevacid® SoluTab Delayed-Release Orally Disintegrating Tablets

PR-M12-18-NI-022
Probiotics

Hard-Shell Capsule Solutions for Sensitive Compounds: A Focus on Probiotics

PAO-M12-18-CL-002
Clinical Trials

Late-Breaking Clinical Trials Advance Targeted Therapies for Patients with CLL and Multiple Myeloma

PR-M12-18-NI-018
Drug Development

Aquestive Therapeutics Announces Late-Breaking Findings of its Investigational Diazepam Buccal Film (DBF) Formulation in Adults with Epilepsy

PR-M12-18-NI-016
Phase 3

New DARZALEX® (daratumumab) Phase 3 Study Shows Efficacy and Safety Data of Anti-CD38 Monoclonal Antibody in Patients with Newly Diagnosed Multiple Myeloma

PR-M12-18-NI-019
Oncology

IMBRUVICA® (ibrutinib) Combination Regimen Significantly Improved Survival Versus the Chemoimmunotherapy FCR

PR-M12-18-NI-017
Oncology

New Phase 3 CASSINI Data Presented on the Use of XARELTO® (rivaroxaban) for Venous Thromboembolism (VTE) Prevention in High-Risk Cancer Patients

PR-M12-18-NI-020
Bayer

Cutbacks and Divestitures Planned at Bayer

PAO-M12-18-NI-004
FDA

FDA Gives Novartis Gene Replacement Therapy Application Priority Review

PAO-M12-18-NI-003
Acquisition

GSK Acquires Oncology Company Tesaro

PAO-M12-18-NI-008
Acquisition

Unilever’s Indian Subsidiary to Acquire GSK’s Consumer Nutrition Brands in India

PAO-M12-18-NI-002
Bispecific Antibody

Regeneron’s Bispecific Antibody Candidate Shows Positive Results in Early Clinical Studies

PAO-M12-18-NI-007
Licensing Agreement

Pfizer to License AbbVie’s Humira IP

PAO-M12-18-NI-006
Collaboration Agreement

Cilag GmbH to Collaborate with argenx on New Treatment for AML, MDS

PAO-M12-18-NI-005
Biosimilars

Pfizer’s Rituximab Biosimilar Achieves Positive Study Results

PAO-M12-18-NI-001
Equipment

Steps Ahead: Planning for Future Equipment Surpluses from the Point of Procurement

PAO-M12-18-CL-001
Epilepsy

New Analyses Evaluate Long-Term Convulsive Seizure Freedom Rates With Use Of Adjunctive FYCOMPA® (perampanel) CIII In Adult Patients Presented at Annual Meeting of the AES

PR-M12-18-NI-015
Alzheimer's Disease

Ocular Technology Provides Early Detection of Alzheimer's Disease

PR-M12-18-NI-014
Immunotherapy

Global Cancer Immunotherapy Market 2017-2027 Featuring Leading Players - Pfizer, Merck, Amgen and Roche

PR-M12-18-NI-012
Cystic Fibrosis

Aridis Expands Research Agreement with the Cystic Fibrosis Foundation and is Awarded FDA Expedited Program Designations

PR-M12-18-NI-013
Cell Therapy

Immunotherapy Pioneers a Unveil Updated Efficacy Data of Tisagenlecleucel, plus Checkpoint Inhibitor Research to Boost Response of CAR T-cell Gene Immunotherapy

PR-M12-18-NI-011
ADC

Ajinomoto Bio-Pharma Services Introduces AJICAP Bioconjugation Technology for ADC Manufacturing

PR-M12-18-NI-010
Market Prediction

The global single-use bioprocessing market is anticipated to reach revenues of approximately $7 billion by 2024

PR-M12-18-NI-009
Stem Cells

Platelets Grown from Stem Cells May be Alternative to Donated Platelets

PR-M12-18-NI-006
Awards

WuXi AppTec Receives 2018 Global Integrated Drug R&D Services Competitive Strategy Innovation & Leadership Award from Frost & Sullivan

PR-M12-18-NI-008
FDA Statement

Statement from FDA Commissioner Scott Gottlieb, M.D., on how modern predicates can promote innovation and advance safety and effectiveness of medical devices that use 510(k) pathway

PR-M12-18-NI-007
Acquisition

CVS Health Completes Acquisition of Aetna, Marking the Start of Transforming the Consumer Health Experience

PR-M12-18-NI-005
FDA Approval

FDA Approves First Biosimilar for Treatment of Adult Patients with Non-Hodgkin's Lymphoma

PR-M12-18-NI-004
Partnership

WuXi Biologics and ABL Bio Enter an Exclusive Development and Clinical Manufacturing Partnership for Multiple Bispecific Antibodies

PR-M12-18-NI-003
Research

Researchers Regrow Hair on Wounded Skin

PR-M12-18-NI-002
Clinical Trial

First Trial Launches to Test Effectiveness of Male Contraceptive Gel

PR-M12-18-NI-001
Capsule

How to Tell If You’re Using a Quality Hard Capsule

PAO-M11-18-CL-001
FDA Approval

Perrigo Announces Tentative FDA Approval for the First To file Generic Version Of Ultravate® Lotion 0.05%

PR-M11-18-NI-107
Vaccine

Tactiva Therapeutics Announces License to Oncolytic Vaccinia Virus Armed With CXCR4 Antagonist for Treatment of Ovarian Cancer

PR-M11-18-NI-109
Agreement

REGENXBIO and Rocket Pharmaceuticals Announce New License Agreement for the Treatment of Danon Disease Using NAV AAV9 Vector

PR-M11-18-NI-108
Market Prediction

The Global Cell Therapy Market Size is Expected to Reach USD 7.92 Billion by 2025

PR-M11-18-NI-106
FDA Approval

FDA Approves an Oncology Drug that Targets a Key Genetic Driver of Cancer, Rather than a Specific Type of Tumor

PR-M11-18-NI-105
Probiotics

Probiotic Ingredients Market Worth Over $3 Billion by 2024: Global Market Insights, Inc.

PR-M11-18-NI-103
Respiratory

Theravance Biopharma Announces First Subject Dosed in Phase 1 Clinical Trial of TD-8236, a Novel Inhaled pan-JAK Inhibitor

PR-M11-18-NI-102
FDA Approval

FDA Approves Vitrakvi® (larotrectinib), the First Ever TRK Inhibitor, for Patients with Advanced Solid Tumors Harboring an NTRK Gene Fusion(1,2)

PR-M11-18-NI-104
Awards

MilliporeSigma Wins Two R&D 100 Awards for Innovation in 2018

PR-M11-18-NI-101
Financing

Antios Therapeutics Raises $25 Million in Oversubscribed Series A Financing to Pursue Hepatitis B Cure

PR-M11-18-NI-100
Acquisition

Interventional Medicine Maker BTG Will Be Purchased by Boston Scientific

PAO-M11-18-NI-030
Clinical Study

Clinical Study Explores the Efficacy of Numerous Ebola Therapies

PAO-M11-18-NI-029
Research

Researchers Discover Potential Cause for Alzheimer’s Disease

PAO-M11-18-NI-028
FDA

First Treatment for Primary Hemophagocytic Lymphohistiocytosis Approved by FDA

PAO-M11-18-NI-027
Facility

WuXi Biologics Breaks Ground on Innovation Center in China

PAO-M11-18-NI-026
FDA Approval

FDA Approves New Bone Cancer Drug

PAO-M11-18-NI-025
CRISPR

CRISPR Used to Edit Genes in Human Embryos

PAO-M11-18-NI-024
Launch

Perrigo Launches Its AB Rated Generic Version of Solaraze® Gel 3%

PR-M11-18-NI-100
Research

Newfound Mechanism May Yield Ways to Counter Mistaken Immune Attack on Body

PR-M11-18-NI-097
Market Prediction

Cannabis Market Worth $39.4 Billion by 2023 - Exclusive Report by MarketsandMarkets™

PR-M11-18-NI-099
Clinical Trial

QPS Expands U.S.-Based Phase I Clinical Trial Capabilities to Support the Growing Needs of Its Pharmaceutical, Biotechnology and CRO Partners

PR-M11-18-NI-098
Facility

GE Healthcare to Open Biotechnology Manufacturing Center in UK

PR-M11-18-NI-096
3D Printing

3D Systems' Medical Workflow Enables OpHeart's Mission with 3D Printed Anatomical Models for Pediatric Heart Surgeries

PR-M11-18-NI-095
FDA Statement

Statement from FDA Commissioner Scott Gottlieb, M.D. and Jeff Shuren, M.D., Director of the CDRH, on FDA's  Medical Device Safety Action Plan to enhance post-market safety

PR-M11-18-NI-094
FDA Inspection

Mylan Statement in Response to FDA Warning Letter Relating to Morgantown Plant

PR-M11-18-NI-093
Crohn's Disease

Theravance Biopharma Announces First Patient Dosed in Phase 2 Study of TD-1473 in Patients with Crohn's Disease

PR-M11-18-NI-092
New Facility

Fresenius Leases Space at Enterprise Business Park

PR-M11-18-NI-091
Launch

Astellas Global Health Foundation Launches

PR-M11-18-NI-087
Collaboration

TARGET PharmaSolutions® to Advance Research in NASH and Hepatitis B Through New Collaboration with Gilead Sciences

PR-M11-18-NI-089
Recall

Mylan Initiates Voluntary Nationwide Recall Due to the Detection of Trace Amounts of NDEA

PR-M11-18-NI-087
FDA

FDA Warns Marketers of Products Labeled as Dietary Supplements that Contain Tianeptine for Making Unproven Claims to Treat Serious Conditions

PR-M11-18-NI-090
FDA Approval

FDA Approves First Treatment Specifically for Patients with Rare and Life-threatening Type of Immune Disease

PR-M11-18-NI-086
CRISPR

CRISPR Technology Market Worth $1,715 Million by 2023 - Exclusive Report by MarketsandMarkets™

PR-M11-18-NI-083
Oncology

World Institute of Kimchi: Function-enhanced kimchi inhibits growth of cancer cells

PR-M11-18-NI-081
Positive Opinion

Amgen Receives CHMP Positive Opinion To Expand Use Of BLINCYTO® (Blinatumomab)

PR-M11-18-NI-74
FDA

FDA Approves First-line Treatment for Peripheral T-cell Lymphoma Under New Review Pilot

PR-M11-18-NI-080
Clinical Trial

Auritec Pharmaceuticals Completes Enrollment for its Sustained-release Depot Tacrolimus Clinical Trial

PR-M11-18-NI-078
Facility

CASI Pharmaceuticals To Build GMP Manufacturing Site In Wuxi, China

PR-M11-18-NI-085
Clinical Trial

Promentis Pharmaceuticals Announces Successful Completion of Phase 1 Studies for SXC-2023 Targeting Novel Glutamatergic Mechanism

PR-M11-18-NI-084
Oncology

New Study Makes Important Step Toward Treatment of Deadly Brain Cancer

PR-M11-18-NI-073
Clinical Trials

Sollis Therapeutics Announces the First Patient Enrolled in a Phase 3 Clinical Trial of Clonidine Micropellet for Sciatica

PR-M11-18-NI-078
Clinical Trials

AIVITA Biomedical Announces Treatment of First Two Patients in Phase 2 Glioblastoma Trial

PR-M11-18-NI-073
Market Prediction

Global $60+ Billion Blockbuster Oncology Brands Market to 2027 Featuring Bristol Myers Squibb, Merck & Co, Roche, Pfizer, Astrazeneca & Tesaro

PR-M11-18-NI-072
FDA

Statement by FDA Commissioner Scott Gottlieb, M.D., on the FDA's Efforts to Hold Industry Accountable for Fulfilling Critical Post-marketing Studies

PR-M11-18-NI-077
PR-M11-18-NI-076

Statement by FDA Commissioner Scott Gottlieb, M.D., on Efforts to Reduce Animal Testing Through a Study Aimed at Eliminating the Use of Dogs in Certain Trials

PR-M11-18-NI-075
Finance

Kodiak Sciences Announces Third Quarter 2018 Financial Results and Recent Business Highlights

PR-M11-18-NI-071
Oncology

Radiotherapy Makes a Comeback

PAO-M11-18-NI-023
Immunotherapy

Patient Weight Can Impact the Effectiveness of Cancer Immunotherapies

PAO-M11-18-NI-022
Clinical Trials

Phase III Study Results for Peanut Allergy Therapy Are a Mixed Bag

PAO-M11-18-NI-021
FDA Approval

Novartis’ Promacta Gets Expanded Use Approval from the FDA

PAO-M11-18-NI-020
Drug Development

EMA Recommends Approval of the First Oral Drug for Sleeping Sickness

PAO-M11-18-NI-019
Pricing

More Price Hikes Coming from Pfizer Next Year

PAO-M11-18-NI-018
Partnership

Immunocore Expands Partnership with Roche

PAO-M11-18-NI-017
Recall

Sandoz Issues Voluntary Recall of Losartan

PAO-M11-18-NI-016
Clinical Results

Theranica Announces Results from Pivotal Study of Device for Treating Acute Migraine

PR-M11-18-NI-066
Clinical Results

BAROnova's TransPyloric Shuttle® (TPS®) Positive Pivotal Trial Data Presented at the 2018 Obesity Week Conference

PR-M11-18-NI-070
Partnership

Entrinsic Health Solutions and Nestlé Health Science Enter Global Partnership for Novel Amino Acid Product enterade®

PR-M11-18-NI-069
Press Releases

New Approvals Allow Chronic Pain Sufferers to Try Abbott's Non-Opioid Pain Therapy Before Getting Device Implant

Clinical Data

DNAtrix To Present Interim Phase 2 Results of DNX-2401 with Pembrolizumab for Glioblastoma

PR-M11-18-NI-067
Clinical Study

Pulmatrix to Present Results from the Pulmazole (PUR1900) Phase 1/1b Study at 2018 Annual Scientific Meeting

PR-M11-18-NI-063
Oncology

Cervical Cancer Treatment: Cure Is Possible If Patients Receive Brachytherapy

PR-M11-18-NI-065
Acquisition

Synteract Acquires Pediatric CRO KinderPharm to Further Strengthen its Pediatric Center of Development

PR-M11-18-NI-064
Research

New Finding Adds Proof Microbes are at Alzheimer's "Crime Scene," Says Dr. Leslie Norins, CEO of Alzheimer's Germ Quest, Inc.

PR-M11-18-NI-062
Drug Development

Published Study: Pycnogenol® Measurably Improved Symptoms Related to Enlarged Prostate Within 60 Days

PR-M11-18-NI-061
License Agreement

Arena Pharmaceuticals and United Therapeutics Announce Global License Agreement for Ralinepag

PR-M11-18-NI-059
FDA

Statement from FDA Commissioner Scott Gottlieb, M.D., on Proposed New Steps to Protect Youth by Preventing Access to Flavored Tobacco Products

PR-M11-18-NI-058
Oncology

Patients Launch New Study to Shed Light on EGFR-Positive Lung Cancers

PR-M11-18-NI-060
Innovation

NIH $1.4M Grant Supports Study into Precision Bioelectronic Medicine

PR-M11-18-NI-057
Market Prediction

Dermatological Drugs: Worldwide Market Analysis & Outlook to 2022 - The Emergence of Improved Diagnostic Modalities is Driving Growth

PR-M11-18-NI-056
Pediatric

American Diabetes Association® Issues Position Statement on Comprehensive Care of Pediatric Patients with Type 2 Diabetes

PR-M11-18-NI-051
Drug Pricing

Gemini Health and Surescripts Partner to Lower Drug Costs through Prescription Price Transparency at the Point of Prescribing

PR-M11-18-NI-055
Press Releases

Newly Published Feeding Trial Showed Cranberries Reduced the Negative Impact of a Low Fiber, Animal-Based Diet on Gut Health

PR-M11-18-NI-054
×